Logo image of LYEL

LYELL IMMUNOPHARMA INC (LYEL) Stock Fundamental Analysis

NASDAQ:LYEL - Nasdaq - US55083R1041 - Common Stock - Currency: USD

8.96  -0.33 (-3.55%)

Fundamental Rating

3

Taking everything into account, LYEL scores 3 out of 10 in our fundamental rating. LYEL was compared to 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LYEL as it has an excellent financial health rating, but there are worries on the profitability. LYEL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LYEL had negative earnings in the past year.
LYEL had a negative operating cash flow in the past year.
LYEL had negative earnings in each of the past 5 years.
In the past 5 years LYEL always reported negative operating cash flow.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

LYEL has a worse Return On Assets (-77.83%) than 69.53% of its industry peers.
LYEL has a Return On Equity (-99.41%) which is in line with its industry peers.
Industry RankSector Rank
ROA -77.83%
ROE -99.41%
ROIC N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LYEL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

8

2. Health

2.1 Basic Checks

LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYEL has more shares outstanding than it did 1 year ago.
LYEL has less shares outstanding than it did 5 years ago.
LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 12.14 indicates that LYEL is not in any danger for bankruptcy at the moment.
LYEL's Altman-Z score of 12.14 is amongst the best of the industry. LYEL outperforms 88.89% of its industry peers.
LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.14
ROIC/WACCN/A
WACC8.94%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

LYEL has a Current Ratio of 7.49. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LYEL (7.49) is better than 68.28% of its industry peers.
A Quick Ratio of 7.49 indicates that LYEL has no problem at all paying its short term obligations.
LYEL has a better Quick ratio (7.49) than 68.64% of its industry peers.
Industry RankSector Rank
Current Ratio 7.49
Quick Ratio 7.49
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

LYEL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -906.33%.
The Revenue for LYEL has decreased by -14.47% in the past year. This is quite bad
Measured over the past years, LYEL shows a very negative growth in Revenue. The Revenue has been decreasing by -37.89% on average per year.
EPS 1Y (TTM)-906.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1400%
Revenue 1Y (TTM)-14.47%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%133.33%

3.2 Future

Based on estimates for the next years, LYEL will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.49% on average per year.
The Revenue is expected to grow by 11.50% on average over the next years. This is quite good.
EPS Next Y-212.22%
EPS Next 2Y-68.22%
EPS Next 3Y-23.49%
EPS Next 5YN/A
Revenue Next Year7.59%
Revenue Next 2Y-3.87%
Revenue Next 3Y11.5%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LYEL. In the last year negative earnings were reported.
Also next year LYEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

LYEL's earnings are expected to decrease with -23.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.22%
EPS Next 3Y-23.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LYEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (6/26/2025, 2:22:00 PM)

8.96

-0.33 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-07 2025-08-07
Inst Owners55.73%
Inst Owner Change1.42%
Ins Owners0.34%
Ins Owner Change2.55%
Market Cap2.65B
Analysts46.67
Price Target16.32 (82.14%)
Short Float %N/A
Short Ratio17.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.69%
Min EPS beat(2)-15.34%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)4.3%
Min EPS beat(4)-15.34%
Max EPS beat(4)16.67%
EPS beat(8)6
Avg EPS beat(8)10.99%
EPS beat(12)10
Avg EPS beat(12)21.62%
EPS beat(16)12
Avg EPS beat(16)7.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1900%
PT rev (3m)1900%
EPS NQ rev (1m)-2090.48%
EPS NQ rev (3m)-1929.41%
EPS NY rev (1m)-1831.27%
EPS NY rev (3m)-1921.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40711.48
P/FCF N/A
P/OCF N/A
P/B 7.86
P/tB 7.86
EV/EBITDA N/A
EPS(TTM)-7.95
EYN/A
EPS(NY)-12.99
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.83%
ROE -99.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 177.45%
Cap/Sales 49270.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.49
Quick Ratio 7.49
Altman-Z 12.14
F-Score3
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)103.35%
Cap/Depr(5y)398.19%
Cap/Sales(3y)18080.8%
Cap/Sales(5y)11104.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-906.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1400%
EPS Next Y-212.22%
EPS Next 2Y-68.22%
EPS Next 3Y-23.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.47%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%133.33%
Revenue Next Year7.59%
Revenue Next 2Y-3.87%
Revenue Next 3Y11.5%
Revenue Next 5YN/A
EBIT growth 1Y7.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.07%
EBIT Next 3Y-7.28%
EBIT Next 5YN/A
FCF growth 1Y-12.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.29%
OCF growth 3YN/A
OCF growth 5YN/A